Literature DB >> 27191934

Human Infection with Influenza A(H7N9) Virus during 3 Major Epidemic Waves, China, 2013-2015.

Peng Wu, Zhibin Peng, Vicky J Fang, Luzhao Feng, Tim K Tsang, Hui Jiang, Eric H Y Lau, Juan Yang, Jiandong Zheng, Ying Qin, Zhongjie Li, Gabriel M Leung, Hongjie Yu, Benjamin J Cowling.   

Abstract

Since March 2013, a novel influenza A(H7N9) virus has caused 3 epidemic waves of human infection in mainland China. We analyzed data from patients with laboratory-confirmed influenza A(H7N9) virus infection to estimate the risks for severe outcomes after hospitalization across the 3 waves. We found that hospitalized patients with confirmed infections in waves 2 and 3 were younger and more likely to be residing in small cities and rural areas than were patients in wave 1; they also had a higher risk for death, after adjustment for age and underlying medical conditions. Risk for death among hospitalized patients during waves 2 and 3 was lower in Jiangxi and Fujian Provinces than in eastern and southern provinces. The variation in risk for death among hospitalized case-patients in different areas across 3 epidemic waves might be associated with differences in case ascertainment, changes in clinical management, or virus genetic diversity.

Entities:  

Keywords:  China; clinical severity; epidemiology; influenza; influenza A(H7N9); respiratory infections; viruses

Mesh:

Year:  2016        PMID: 27191934      PMCID: PMC4880089          DOI: 10.3201/eid2206.151752

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


More than 3 years have passed since novel influenza A(H7N9) virus infections were first detected among humans in mainland China (). The first epidemic of human infections occurred in the spring of 2013; 134 cases were laboratory confirmed through September 2013 (control measures in combination with environmental factors led to a lull in incidence in the summer of 2013) (,). However, a second epidemic of infections occurred in the winter of 2013–14 (), and a third epidemic occurred in the winter of 2014–15. A fourth wave is ongoing, and as of March 3, 2016, in mainland China, 730 laboratory-confirmed human cases of influenza A(H7N9) virus infection have been reported, most associated with severe disease; 295 of the infections were fatal. Low pathogenicity of influenza A(H7N9) infections in chickens has been well established (), and most human infections can be attributed to close contact with infected chickens, particularly in live poultry markets (,,). The objectives of this study were to compare the epidemiology of human cases of influenza A(H7N9) infection across the 3 epidemics and, in particular, to examine whether the severity of disease among hospitalized case-patients has changed over time. To do this, we estimated the risks for death, use of mechanical ventilation, and admission to an intensive care unit (ICU) among hospitalized patients with severe infections caused by influenza A(H7H9) virus.

Methods

Source of Data

All laboratory-confirmed cases of avian influenza A(H7N9) virus infection in mainland China are reported to the Chinese Center for Disease Control and Prevention (China CDC) through a national surveillance system. Case definitions, surveillance for identification of cases, and laboratory assays have been described (,). Demographic, epidemiologic, and basic clinical data on each confirmed case-patient were obtained on standardized forms and entered into an integrated database at China CDC. We based our analyses on the version of this database existing on June 15, 2015; we retrieved information about patient age, sex, place of residence, occupation, underlying medical conditions, potential exposure to live poultry, dates of illness onset, hospital admission, ICU admission, mechanical ventilation, death, and recovery or discharge.

Ethical Approval

The National Health and Family Planning Commission ruled that the collection of data for laboratory-confirmed cases of influenza A(H7N9) virus infection was part of a continuing public health investigation of an emerging outbreak. The study was therefore exempt from institutional review board assessment.

Statistical Analysis

We analyzed data on the severity of laboratory-confirmed case-patients who were hospitalized for medical reasons (rather than for the sole purpose of isolating them from the community) on the basis of clinical judgment (e.g., those exhibiting complications such as pneumonia). After excluding a small number of case-patients who had mild respiratory symptoms and had been hospitalized only for the purpose of isolation, we estimated the risks of ICU admission, mechanical ventilation, and death after hospitalization (). The number of such cases was small, and inclusion of these cases in analyses did not have any effect on the conclusions. We also excluded case-patients for whom clinical outcomes were not reported from the analysis of severity. We estimated the risk for ICU admission, mechanical ventilation, and death following hospitalization by dividing the number of case-patients who were admitted to ICU, treated with mechanical ventilation, or died by the number of all case-patients with definite clinical outcomes. We derived binomial 95% CIs for each point estimate of severity among hospitalized case-patients. We examined epidemiologic time-to-event distributions using kernel density methods as described () and conducted a logistic regression analysis to investigate potential factors affecting the risk for death among hospitalized patients infected with influenza A(H7N9) virus in 3 waves. We estimate adjusted odds ratios and 95% CIs for potential risk factors, including age, sex, place of residence, underlying medical conditions, and time delay from symptom onset to hospital admission. We performed all statistical analyses by using R version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Three major epidemics of human influenza A(H7N9) virus infections have occurred since the first human case was identified in March 2013: spring 2013, winter–spring of 2013–14, and winter–spring of 2014–15 (Figure 1; Technical Appendix). The median age of confirmed case-patients in each of the 3 epidemics was 61 years, 57 years, and 56 years, respectively. Most patients with laboratory-confirmed cases were men, and a substantial proportion of case-patients had underlying medical conditions (Table 1). Approximately half of the laboratory-confirmed cases in the first wave were detected in municipalities or provincial capital cities such as Shanghai, Hangzhou, and Nanjing; in the second and third waves, most of the case-patients were from smaller cities or rural areas (Table 1; Technical Appendix).
Figure 1

Weekly hospital admissions of human case-patients with laboratory-confirmed influenza A(H7N9) virus infection in 3 epidemic waves, China, 2013–2015.

Table 1

Characteristics of laboratory-confirmed influenza A(H7N9) cases detected in 3 epidemic waves, China, 2013–2015

CharacteristicNo. (%) cases
Wave 1A, Jan 2013–Mar 2013, n = 19Wave 1B, Apr 2013–Sep 2013, n = 115Wave 2, Oct 2013–Sep 2014, n = 306Wave 3, Oct 2014–Mar 2015, n = 215
Age group, y
0–151 (5)6 (5)19 (6)17 (8)
16–598 (42)47 (41)151 (49)113 (53)
60–748 (42)37 (32)89 (29)58 (27)
>752 (11)25 (22)47 (15)27 (13)
Median
60
61
57
56
Male sex
13 (68)
81 (70)
212 (69)
154 (72)
Residence*
Provincial capital or municipality10 (53)58 (50)57 (19)22 (10)
Other cities6 (32)23 (20)131 (43)100 (47)
Rural areas
3 (16)
34 (30)
118 (39)
93 (43)
Presence of ≥1 underlying medical condition†
10 (53)
42 (37)
91 (30)
64 (30)
Onset to hospital admission, d
0–22 (11)12 (10)41 (14)32 (18)
3–68 (44)62 (54)151 (52)84 (46)
>7
8 (44)
41 (36)
96 (33)
65 (36)
Poultry exposure
Any exposure to poultry15 (79)91 (83)165 (81)116 (74)
Occupational exposure to live poultry1 (5)6 (5)21 (7)22 (10)
Visited live poultry market12 (63)62 (54)132 (61)105 (67)
Exposure to sick or dead poultry0 (0)3 (3)3 (1)7 (5)
Exposure to backyard poultry6 (35)48 (49)34 (20)4 (2)

*For more information, see the online Technical Appendix (http://wwwnc.cdc.gov/EID/article/22/6/15-1752-Techapp1.pdf).
†Only underlying medical disorders associated with a high risk for influenza complications were counted here, including chronic respiratory disease, asthma, chronic cardiovascular disease, diabetes, chronic liver disease, chronic kidney disease, immunosuppressed status, and neuromuscular disorders.

Weekly hospital admissions of human case-patients with laboratory-confirmed influenza A(H7N9) virus infection in 3 epidemic waves, China, 2013–2015. *For more information, see the online Technical Appendix (http://wwwnc.cdc.gov/EID/article/22/6/15-1752-Techapp1.pdf).
†Only underlying medical disorders associated with a high risk for influenza complications were counted here, including chronic respiratory disease, asthma, chronic cardiovascular disease, diabetes, chronic liver disease, chronic kidney disease, immunosuppressed status, and neuromuscular disorders. Although human cases in the first epidemic were concentrated in the Yangtze River delta (Figure 2, panel A), human cases in the second and third epidemics occurred across a broader swathe of the country (Figure 2, panels B and C). A separate study that used virus sequence data showed that the viruses in the different parts of China had diverged by the start of the second epidemic, forming 3 separate clades (Figure 2, panel D) ().
Figure 2

Geographic distribution of human cases of laboratory-confirmed influenza A(H7N9) virus infection, China, 2013–2015. A) Cases detected in wave 1A (white dots) and wave 1B (light blue dots); B) cases detected in wave 2 (medium blue dots); C) cases detected in wave 3 (dark blue dots); D) cases detected in eastern China (red), Jiangxi and Fujian Provinces (green), and Guangdong Province (yellow).

Geographic distribution of human cases of laboratory-confirmed influenza A(H7N9) virus infection, China, 2013–2015. A) Cases detected in wave 1A (white dots) and wave 1B (light blue dots); B) cases detected in wave 2 (medium blue dots); C) cases detected in wave 3 (dark blue dots); D) cases detected in eastern China (red), Jiangxi and Fujian Provinces (green), and Guangdong Province (yellow). We previously divided the first epidemic into 2 parts—wave 1A for case-patients hospitalized before April 1, 2013, and wave 1B for case-patients hospitalized from April 1 to September 30, 2013—because of higher risks for among case-patients hospitalized before March 31, 2013, the date when the first confirmed human cases of influenza A(H7N9) virus infection were officially announced in China (). We then estimated clinical severity among hospitalized case-patients as measured by hospitalization fatality risk, mechanical ventilation fatality risk, and ICU fatality risk over 3 waves (with wave 1 divided into 2 parts) (Figure 3). Apart from wave 1A, which included mainly retrospective detection of severe cases, some evidence indicated that the severity of hospitalized case-patients increased over time, with statistically significantly higher risk for death among hospitalized patients in wave 3 than for case-patients in wave 1B among those <60 years of age and >60 years of age (Figure 3).
Figure 3

Estimated risk for serious outcomes among patients with confirmed cases of influenza A(H7N9) virus infection hospitalized for medical reasons and 95% CIs, by age and epidemic wave, China, 2013–2015. A) Risk for death; B) risk for death or mechanical ventilation; C) risk for death or mechanical ventilation or intensive care unit admission. The periods covered by waves 1A, 1B, 2, and 3 are shown in Figure 1.

Estimated risk for serious outcomes among patients with confirmed cases of influenza A(H7N9) virus infection hospitalized for medical reasons and 95% CIs, by age and epidemic wave, China, 2013–2015. A) Risk for death; B) risk for death or mechanical ventilation; C) risk for death or mechanical ventilation or intensive care unit admission. The periods covered by waves 1A, 1B, 2, and 3 are shown in Figure 1. We then examined whether these differences in risk for death could be explained by changes in the characteristics of patients across the 3 waves. In a regression analysis, we found that hospitalized case-patients in wave 2 or 3 had a higher risk for death than those in wave 1B after adjusting for patients’ demographic characteristics and underlying medical conditions (Table 2). The higher risk for death observed in waves 2 and 3 remained significant after further adjustment for patients’ residence and delay from symptom onset to hospital admission (Table 2). Patients >60 years of age had a higher risk for death, and rural patients were less likely to die than urban patients.
Table 2

Comparison of risk of death among patients with laboratory-confirmed influenza A(H7N9) virus infection detected in 3 epidemic waves, China, 2013–2015

CharacteristicLaboratory-confirmed H7N9 deaths, adjusted odds ratio (95% CI)
Model 1Model 2
Wave
1A4.88 (1.64–14.53)5.07 (1.67–15.46)
1B1.001.00
22.39 (1.46–3.91)3.48 (2.00–6.06)
3
3.93 (2.30–6.72)
4.84 (2.66–8.80)
Age group, y
0–150.56 (0.05–5.78)0.50 (0.05–5.43)
16–591.001.00
60–742.05 (1.38–3.04)2.09 (1.34–3.26)
>75
2.88 (1.75–4.74)
2.49 (1.44–4.30)
Sex
F1.001.00
M
1.00 (0.68–1.46)
0.94 (0.61–1.45)
Underlying medical conditions
No underlying medical disorder1.001.00
>1 underlying medical condition*
1.28 (0.88–1.84)
1.22 (0.82–1.81)
Residence
Residence in a provincial capital or municipality1.00
Residence in other cities§0.52 (0.30–0.89)
Rural residence

0.53 (0.31–0.91)
Onset to final hospital admission, d
0–41.00
5–71.21 (0.77–1.90)
>71.19 (0.72–1.95)

*Only underlying medical disorders associated with a high risk for influenza complications were counted here, including chronic respiratory disease, asthma, chronic cardiovascular disease, diabetes, chronic liver disease, chronic kidney disease, immunosuppressed status, and neuromuscular disorders.

*Only underlying medical disorders associated with a high risk for influenza complications were counted here, including chronic respiratory disease, asthma, chronic cardiovascular disease, diabetes, chronic liver disease, chronic kidney disease, immunosuppressed status, and neuromuscular disorders. We conducted a further analysis to investigate the risk for death among patients in different geographic locations where research suggested that circulating influenza A(H7N9) viruses belonged to different genetic clades (Figure 4) (). We found that hospitalized case-patients detected in Jiangxi and Fujian in wave 3 had a lower risk for death than case-patients reported in eastern China, including Shanghai, Zhejiang Province, and Jiangsu Province, particularly in the third wave, as well as in Guangdong Province in southern China. However, the severity of infection in hospitalized case-patients was similar in patients detected in waves 2 and 3 in Jiangxi and Fujian Provinces (Figure 4).
Figure 4

Comparison of risk for death among hospitalized patients with laboratory-confirmed influenza A(H7N9) virus infection detected in 3 areas of China where circulating influenza A(H7N9) viruses might belong to distinct genetic clades, 2013–2015. A) Odds ratios for death, adjusted for age, sex, patient’s residence, underlying medical conditions, and delay from onset to hospital admission; B) symptom onsets of case-patients detected in 3 areas; C) geographic distribution of cases detected in 3 areas. The periods covered by waves 2 and 3 are shown in Figure 1.

Comparison of risk for death among hospitalized patients with laboratory-confirmed influenza A(H7N9) virus infection detected in 3 areas of China where circulating influenza A(H7N9) viruses might belong to distinct genetic clades, 2013–2015. A) Odds ratios for death, adjusted for age, sex, patient’s residence, underlying medical conditions, and delay from onset to hospital admission; B) symptom onsets of case-patients detected in 3 areas; C) geographic distribution of cases detected in 3 areas. The periods covered by waves 2 and 3 are shown in Figure 1. We found estimates of the incubation period (Figure 5, panel A) and the time from illness onset to laboratory confirmation (Figure 5, panel C) consistent across the 3 waves. The time from illness onset to hospital admission was relatively shorter in more recent waves than in previous waves (Figure 5, panel B). The mean time from illness onset to laboratory confirmation was 8.0 days in wave 1B, 9.0 days in wave 2, and 8.4 days in wave 3 (analysis of variance, p = 0.44). The time from final hospital admission to death was longer for patients detected in the third wave than for patients from wave 1B and wave 2, whereas the distribution of the interval was similar for wave 3 and 1A (Figure 5, panel D). The time from hospital admission to discharge was generally similar across different epidemic waves (Figure 5, panel E).
Figure 5

Time to event distributions of influenza A(H7N9) virus infections across different epidemic waves. A) Time from potential exposure to illness onset; B) time from illness onset to hospital admission; C) time from illness onset to laboratory confirmation; D) time from hospital admission to death; E) time from hospital admission to discharge. The periods covered by waves 1A, 1B, 2, and 3 are shown in Figure 1.

Time to event distributions of influenza A(H7N9) virus infections across different epidemic waves. A) Time from potential exposure to illness onset; B) time from illness onset to hospital admission; C) time from illness onset to laboratory confirmation; D) time from hospital admission to death; E) time from hospital admission to discharge. The periods covered by waves 1A, 1B, 2, and 3 are shown in Figure 1.

Discussion

In this study, we found some evidence that the estimated risk for severe outcomes in hospitalized patients with influenza A(H7N9) virus infection may have increased in some areas across the 3 epidemic waves over time. Although hospitalized patients in the first part of wave 1 (wave 1A) had more severe cases (perhaps because of ascertainment biases) (), hospitalized patients in the main part of the first wave (wave 1B) generally had less severe cases (Figure 3). The risk for death among hospitalized patients in the second and third waves was higher than the risk for younger and older persons in wave 1B (Figure 3), and this finding could not be fully explained by differences in age, prevalence of underlying medical conditions, or urban/rural residence (Table 2). This difference occurred despite a faster time to admission and similar time to laboratory confirmation of cases (Figure 5). This observed increase in estimates of severity of cases among hospitalized patients could be real and indicative of an increase in pathogenicity of the virus in humans, or an artifact of case ascertainment biases. In the first hypothesis, apart from potential changes in the virus, an increase in pathogenicity in hospitalized case-patients would also arise if management and treatment of patients differed between the waves (). Infections in the winter in waves 2 and 3 rather than the spring in wave 1B (Figure 1) might be more severe if other pathogens that could cause secondary or co-infections among infected patients were more prevalent. On the other hand, it is possible that prioritized repeating laboratory testing in the early wave of influenza A(H7N9) virus infections and increased laboratory capacity in testing for the virus, particularly among patients with more severe cases over the past 2 years might have led to an artifactual increase in severity of cases among hospitalized patients (). We also observed that a relatively lower proportion of hospitalized patients in the second and third waves were transferred to major regional referral hospitals than in the first wave, which might contribute to a potential increase of clinical severity among hospitalized case-patients if different hospitals were assumed to vary in their capacity for managing these patients. The relatively lower severity of cases among hospitalized patients estimated in Jiangxi and Fujian Provinces in contrast to the higher severity of hospitalized cases in eastern China and Guangdong Province might be driven by different factors, although the geographic distribution in severity of cases among hospitalized patients was largely consistent with the 3 genetic clades detected in similar areas (). Infections in Jiangxi and Fujian Provinces might be associated with 1 of the 3 clades identified in wave 2 (clade W2-C), whereas the other 2 virus clades originated from provinces in eastern China (clade W2-A) and Guangdong Province (clade W2-B) (), possibly implying a change in virus pathogenesis. Another explanation for the potential increased severity cases among hospitalized patients in these provinces, other than potential viral changes, is that clinical management may have improved in other provinces that acquired more experience in treating these infections. However, this difference may also be an artifact of differential case ascertainment rather than real differences in severity of cases in hospitalized patients, and we did not have access to individual virus sequence data to confirm that each of the cases in Jiangxi and Fujian Provinces was associated with clade W2-C viruses. Across the 3 epidemics, the declining median age of case-patients might result from population-level behavioral changes in exposure to live poultry, particularly in potential high-risk groups such as the elderly, as indicated in previous studies (,). Population contact with live poultry decreased in influenza A(H7N9) virus–affected and –nonaffected areas after cases were detected in China, although exposure to live poultry in urban and rural areas remained high in the country (). Live poultry markets in China, particularly in cities, have been closing either temporarily or permanently since the first wave in 2013 (,). Some cities severely affected by influenza A(H7N9) virus in the Yangtze River Delta permanently closed all live poultry markets in 2014, which led to a substantial decline in population exposure to the virus and the risk for infection. A relatively higher proportion of rural cases were anticipated in later waves than in earlier waves because contact with backyard poultry instead of commercial live poultry in markets accounted for most poultry exposure for residents of rural and semiurban areas (). The similar geographic dispersion of case-patients in wave 2 and 3 matches the areas with the highest poultry density in eastern and southern China () and is also consistent with virus genetic findings that new virus clades originating from eastern China in wave 2 might have been well established and become endemic locally in southern China or other areas (). Although we have focused on the severity of cases among hospitalized patients, it is also possible to characterize severity in other ways, such as the risk for severe disease among persons with symptomatic influenza A(H7N9) virus infections (,) or the risk for mild and severe disease among all infections. The latter could be estimated if serologic data were available, but few population-based serologic studies of influenza A(H7N9) virus infections have been published (,). Our study is limited by potential underascertainment of hospitalized case-patients, particularly because of the insufficient capacity of health care facilities to deal with a sudden increased need for diagnosis and treatment of patients with severe cases or a decreasing vigilance on influenza A(H7N9) virus infection in population or health care settings. Ascertainment of hospitalized case-patients could also be potentially affected by changes in clinical management or disease surveillance, particularly of severe acute respiratory infections or unexplained pneumonia through which many cases of influenza A(H7N9) virus infection were detected. However, no major changes were identified in clinical and surveillance practice during the study period. The estimates of the risks of serious outcomes among hospitalized patients could be affected by case ascertainment; limited access to laboratory testing, especially in rural areas; and self-reported exposure data by patients that could be subject to reporting and recall bias. We did not have detailed information on clinical management such as oseltamivir use, and therefore we could not explore whether differences in treatment were associated with differences in risk for death. Using a composite endpoint to measure severity of cases in hospitalized patients might provide more information on severe outcomes related to this infection than death only, although use of ventilation and admission to ICUs can be limited by hospital capacity and availability of resources. Inaccuracies in the exact dates of hospitalization and uncertainty about a small proportion (5%) of final outcomes might lead to small biases in our estimates but should not change the overall conclusions of this study. In conclusion, our study explored the epidemiology of human infections with H7N9 virus in mainland China across 3 epidemic waves in 2013–2015. Laboratory-confirmed H7N9 case-patients were younger and more likely to be from small cities and rural areas in wave 2 and wave 3 than in wave 1. Hospitalized H7N9 patients had an increasing risk for death across 3 waves. The increased risk in waves 2 and 3 might imply a changing pathogenesis associated with genetic clades of H7N9 virus that appeared in later epidemic waves or differences in clinical management in different provinces, although case ascertainment bias could not be ruled out.

Technical Appendix

Table shows the number of influenza A(H7N9) cases, deaths, intensive-care-unit admissions, and those on mechanical ventilation reported during epidemic waves in mainland China, 2013–2015, and also a definition of the term residence as used in the study.
  16 in total

1.  Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases.

Authors:  Benjamin J Cowling; Lianmei Jin; Eric H Y Lau; Qiaohong Liao; Peng Wu; Hui Jiang; Tim K Tsang; Jiandong Zheng; Vicky J Fang; Zhaorui Chang; Michael Y Ni; Qian Zhang; Dennis K M Ip; Jianxing Yu; Yu Li; Liping Wang; Wenxiao Tu; Ling Meng; Joseph T Wu; Huiming Luo; Qun Li; Yuelong Shu; Zhongjie Li; Zijian Feng; Weizhong Yang; Yu Wang; Gabriel M Leung; Hongjie Yu
Journal:  Lancet       Date:  2013-06-24       Impact factor: 79.321

2.  Reducing exposure to avian influenza H7N9.

Authors:  Jianguo Xu; Shan Lu; Haiyin Wang; Chen Chen
Journal:  Lancet       Date:  2013-05-10       Impact factor: 79.321

3.  Dissemination, divergence and establishment of H7N9 influenza viruses in China.

Authors:  Tommy Tsan-Yuk Lam; Boping Zhou; Jia Wang; Yujuan Chai; Yongyi Shen; Xinchun Chen; Chi Ma; Wenshan Hong; Yin Chen; Yanjun Zhang; Lian Duan; Peiwen Chen; Junfei Jiang; Yu Zhang; Lifeng Li; Leo Lit Man Poon; Richard J Webby; David K Smith; Gabriel M Leung; Joseph S M Peiris; Edward C Holmes; Yi Guan; Huachen Zhu
Journal:  Nature       Date:  2015-03-11       Impact factor: 49.962

4.  Epidemiology of human infections with avian influenza A(H7N9) virus in China.

Authors:  Qun Li; Lei Zhou; Minghao Zhou; Zhiping Chen; Furong Li; Huanyu Wu; Nijuan Xiang; Enfu Chen; Fenyang Tang; Dayan Wang; Ling Meng; Zhiheng Hong; Wenxiao Tu; Yang Cao; Leilei Li; Fan Ding; Bo Liu; Mei Wang; Rongheng Xie; Rongbao Gao; Xiaodan Li; Tian Bai; Shumei Zou; Jun He; Jiayu Hu; Yangting Xu; Chengliang Chai; Shiwen Wang; Yongjun Gao; Lianmei Jin; Yanping Zhang; Huiming Luo; Hongjie Yu; Jianfeng He; Qi Li; Xianjun Wang; Lidong Gao; Xinghuo Pang; Guohua Liu; Yansheng Yan; Hui Yuan; Yuelong Shu; Weizhong Yang; Yu Wang; Fan Wu; Timothy M Uyeki; Zijian Feng
Journal:  N Engl J Med       Date:  2013-04-24       Impact factor: 91.245

5.  Role of poultry in the spread of novel H7N9 influenza virus in China.

Authors:  Mary J Pantin-Jackwood; Patti J Miller; Erica Spackman; David E Swayne; Leonardo Susta; Mar Costa-Hurtado; David L Suarez
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

6.  Avian-origin influenza A(H7N9) infection in influenza A(H7N9)-affected areas of China: a serological study.

Authors:  Shigui Yang; Yu Chen; Dawei Cui; Hangping Yao; Jianzhou Lou; Zhaoxia Huo; Guoliang Xie; Fei Yu; Shufa Zheng; Yida Yang; Yixin Zhu; Xiaoqing Lu; Xiaoli Liu; Siu-Ying Lau; Jasper Fuk-Woo Chan; Kelvin Kai-Wang To; Kwok-Yung Yuen; Honglin Chen; Lanjuan Li
Journal:  J Infect Dis       Date:  2013-08-09       Impact factor: 5.226

7.  Human infection with a novel avian-origin influenza A (H7N9) virus.

Authors:  Rongbao Gao; Bin Cao; Yunwen Hu; Zijian Feng; Dayan Wang; Wanfu Hu; Jian Chen; Zhijun Jie; Haibo Qiu; Ke Xu; Xuewei Xu; Hongzhou Lu; Wenfei Zhu; Zhancheng Gao; Nijuan Xiang; Yinzhong Shen; Zebao He; Yong Gu; Zhiyong Zhang; Yi Yang; Xiang Zhao; Lei Zhou; Xiaodan Li; Shumei Zou; Ye Zhang; Xiyan Li; Lei Yang; Junfeng Guo; Jie Dong; Qun Li; Libo Dong; Yun Zhu; Tian Bai; Shiwen Wang; Pei Hao; Weizhong Yang; Yanping Zhang; Jun Han; Hongjie Yu; Dexin Li; George F Gao; Guizhen Wu; Yu Wang; Zhenghong Yuan; Yuelong Shu
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

8.  Effect of closure of live poultry markets on poultry-to-person transmission of avian influenza A H7N9 virus: an ecological study.

Authors:  Hongjie Yu; Joseph T Wu; Benjamin J Cowling; Qiaohong Liao; Vicky J Fang; Sheng Zhou; Peng Wu; Hang Zhou; Eric H Y Lau; Danhuai Guo; Michael Y Ni; Zhibin Peng; Luzhao Feng; Hui Jiang; Huiming Luo; Qun Li; Zijian Feng; Yu Wang; Weizhong Yang; Gabriel M Leung
Journal:  Lancet       Date:  2013-10-31       Impact factor: 79.321

9.  Mapping spread and risk of avian influenza A (H7N9) in China.

Authors:  Li-Qun Fang; Xin-Lou Li; Kun Liu; Yin-Jun Li; Hong-Wu Yao; Song Liang; Yang Yang; Zi-Jian Feng; Gregory C Gray; Wu-Chun Cao
Journal:  Sci Rep       Date:  2013-09-26       Impact factor: 4.379

10.  Human infection with avian influenza A H7N9 virus: an assessment of clinical severity.

Authors:  Hongjie Yu; Benjamin J Cowling; Luzhao Feng; Eric H Y Lau; Qiaohong Liao; Tim K Tsang; Zhibin Peng; Peng Wu; Fengfeng Liu; Vicky J Fang; Honglong Zhang; Ming Li; Lingjia Zeng; Zhen Xu; Zhongjie Li; Huiming Luo; Qun Li; Zijian Feng; Bin Cao; Weizhong Yang; Joseph T Wu; Yu Wang; Gabriel M Leung
Journal:  Lancet       Date:  2013-06-24       Impact factor: 79.321

View more
  14 in total

1.  Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series.

Authors:  Xiling Wang; Hui Jiang; Peng Wu; Timothy M Uyeki; Luzhao Feng; Shengjie Lai; Lili Wang; Xiang Huo; Ke Xu; Enfu Chen; Xiaoxiao Wang; Jianfeng He; Min Kang; Renli Zhang; Jin Zhang; Jiabing Wu; Shixiong Hu; Hengjiao Zhang; Xiaoqing Liu; Weijie Fu; Jianming Ou; Shenggen Wu; Ying Qin; Zhijie Zhang; Yujing Shi; Juanjuan Zhang; Jean Artois; Vicky J Fang; Huachen Zhu; Yi Guan; Marius Gilbert; Peter W Horby; Gabriel M Leung; George F Gao; Benjamin J Cowling; Hongjie Yu
Journal:  Lancet Infect Dis       Date:  2017-06-02       Impact factor: 25.071

2.  Sialoglycovirology of Lectins: Sialyl Glycan Binding of Enveloped and Non-enveloped Viruses.

Authors:  Nongluk Sriwilaijaroen; Yasuo Suzuki
Journal:  Methods Mol Biol       Date:  2020

3.  Preliminary Epidemiologic Assessment of Human Infections With Highly Pathogenic Avian Influenza A(H5N6) Virus, China.

Authors:  Hui Jiang; Peng Wu; Timothy M Uyeki; Jianfeng He; Zhihong Deng; Wen Xu; Qiang Lv; Jin Zhang; Yang Wu; Tim K Tsang; Min Kang; Jiandong Zheng; Lili Wang; Bingyi Yang; Ying Qin; Luzhao Feng; Vicky J Fang; George F Gao; Gabriel M Leung; Hongjie Yu; Benjamin J Cowling
Journal:  Clin Infect Dis       Date:  2017-08-01       Impact factor: 20.999

4.  Risk Factors for Influenza A(H7N9) Disease in China, a Matched Case Control Study, October 2014 to April 2015.

Authors:  Lei Zhou; Ruiqi Ren; Jianming Ou; Min Kang; Xiaoxiao Wang; Fiona Havers; Xiang Huo; Xiaoqing Liu; Qianlai Sun; Yongchao He; Bo Liu; Shenggen Wu; Yali Wang; Haitian Sui; Yongjie Zhang; Shaopei Tang; Caiyun Chang; Lunhui Xiang; Dong Wang; Shiguang Zhao; Suizan Zhou; Tao Chen; Nijuan Xiang; Carolyn M Greene; Yanping Zhang; Yuelong Shu; Zijian Feng; Qun Li
Journal:  Open Forum Infect Dis       Date:  2016-08-30       Impact factor: 3.835

5.  Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses.

Authors:  Lei Deng; Teena Mohan; Timothy Z Chang; Gilbert X Gonzalez; Ye Wang; Young-Man Kwon; Sang-Moo Kang; Richard W Compans; Julie A Champion; Bao-Zhong Wang
Journal:  Nat Commun       Date:  2018-01-24       Impact factor: 14.919

6.  Estimating disease burden of a potential A(H7N9) pandemic influenza outbreak in the United States.

Authors:  Walter Silva; Tapas K Das; Ricardo Izurieta
Journal:  BMC Public Health       Date:  2017-11-25       Impact factor: 3.295

7.  Epidemiology of human infections with highly pathogenic avian influenza A(H7N9) virus in Guangdong, 2016 to 2017.

Authors:  Min Kang; Eric H Y Lau; Wenda Guan; Yuwei Yang; Tie Song; Benjamin J Cowling; Jie Wu; Malik Peiris; Jianfeng He; Chris Ka Pun Mok
Journal:  Euro Surveill       Date:  2017-07-06

8.  Predictors for fatal human infections with avian H7N9 influenza, evidence from four epidemic waves in Jiangsu Province, Eastern China, 2013-2016.

Authors:  Wang Ma; Haodi Huang; Jian Chen; Ke Xu; Qigang Dai; Huiyan Yu; Fei Deng; Xian Qi; Shenjiao Wang; Jie Hong; Changjun Bao; Xiang Huo; Minghao Zhou
Journal:  Influenza Other Respir Viruses       Date:  2017-07-26       Impact factor: 4.380

9.  Epidemiological, clinical, and virologic features of two family clusters of avian influenza A (H7N9) virus infections in Southeast China.

Authors:  Jianfeng Xie; Yuwei Weng; Jianming Ou; Lin Zhao; Yanhua Zhang; Jinzhang Wang; Wei Chen; Meng Huang; Wenqiong Xiu; Hongbin Chen; Yongjun Zhang; Binshan Wu; Wenxiang He; Ying Zhu; Libin You; Zhimiao Huang; Canming Zhang; Longtao Hong; Wei Wang; Kuicheng Zheng
Journal:  Sci Rep       Date:  2017-05-04       Impact factor: 4.379

10.  The PB2 mutation with lysine at 627 enhances the pathogenicity of avian influenza (H7N9) virus which belongs to a non-zoonotic lineage.

Authors:  Weixuan Li; Horace Hok Yeung Lee; Run Feng Li; Huachen Maria Zhu; Guan Yi; Joseph Sriyal Malik Peiris; Zi Feng Yang; Chris Ka Pun Mok
Journal:  Sci Rep       Date:  2017-05-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.